Blood:miR-29通过TRAF4调控CLL微环境中的CD40信号

2020-11-30 Nebula-Qin MedSci原创

 

B细胞受体(BCR)信号转导和T细胞相互作用在慢性淋巴细胞白血病(CLL)的发病机制和病程进展中起着关键作用。CLL细胞可以利用microRNAs(MiRNAs)及其靶基因来调节淋巴结壁龛内的微环境相互作用。

为了确定miRNA在CLL微环境中的表达变化,研究人员通过比较CXCR4/CD5克隆内细胞亚群(CXCR4dimCD5bright与CXCR4brightCD5dim细胞),对短链非编码RNA进行了复杂的图谱分析。

两亚群细胞的差异性表达miRNA

结果发现了数十个差异性表达的miRNAs,其中几个已被证明了参与调节BCR信号的miRNAs(miR-155、miR-150和miR-22)。值得注意的是,miR-29家族的全部成员(miR-29a、miR-29b、miR-29c)都在免疫微环境中持续下调,且miR-29(a/b/c)水平的降低与CLL细胞对BCR阻断的相对反应性增强以及CLL患者的总生存期显著缩短有关。

miR-29的表达水平与总生存期的关系

此外,研究人员还发现肿瘤坏死因子受体相关因子4(TRAF4)是miR-29s的一个新的直接靶点,高TRAF4水平可增加CLL对CD40激活和下游NFkB信号的反应性。在CLL中,BCR通过MYC抑制miR-29的表达,同时允许TRAF4上调和CD40-NFkB信号增强。该调控环路可被“BCR抑制剂”(BTK抑制剂依鲁替尼或PI3K抑制剂idelalisib)破坏。

总结模式图

综上所述,该研究首次展示了CLL微环境中激活CD40信号/T细胞相互作用的miRNA依赖性机制,并描述了一个受BCR活性调控的新的miR-29-TRAF4-CD40信号轴。

原始出处:

Sharma Sonali,Pavlasova Gabriela Mladonicka,Seda Vaclav et al. miR-29 Modulates CD40 Signaling in Chronic Lymphocytic Leukemia by Targeting TRAF4: an Axis Affected by BCR inhibitors. Blood, 2020.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1657386, encodeId=07c6165e386b5, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Fri Jun 11 02:21:07 CST 2021, time=2021-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864288, encodeId=e152186428876, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Tue Feb 02 16:21:07 CST 2021, time=2021-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930806, encodeId=22cd193080637, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Fri Feb 26 17:21:07 CST 2021, time=2021-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795820, encodeId=23651e95820b5, content=<a href='/topic/show?id=9f491e726a3' target=_blank style='color:#2F92EE;'>#TRAF4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17726, encryptionId=9f491e726a3, topicName=TRAF4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Mon Aug 30 16:21:07 CST 2021, time=2021-08-30, status=1, ipAttribution=)]
    2021-06-11 bsmagic9140
  2. [GetPortalCommentsPageByObjectIdResponse(id=1657386, encodeId=07c6165e386b5, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Fri Jun 11 02:21:07 CST 2021, time=2021-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864288, encodeId=e152186428876, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Tue Feb 02 16:21:07 CST 2021, time=2021-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930806, encodeId=22cd193080637, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Fri Feb 26 17:21:07 CST 2021, time=2021-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795820, encodeId=23651e95820b5, content=<a href='/topic/show?id=9f491e726a3' target=_blank style='color:#2F92EE;'>#TRAF4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17726, encryptionId=9f491e726a3, topicName=TRAF4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Mon Aug 30 16:21:07 CST 2021, time=2021-08-30, status=1, ipAttribution=)]
    2021-02-02 qidongfanjian
  3. [GetPortalCommentsPageByObjectIdResponse(id=1657386, encodeId=07c6165e386b5, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Fri Jun 11 02:21:07 CST 2021, time=2021-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864288, encodeId=e152186428876, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Tue Feb 02 16:21:07 CST 2021, time=2021-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930806, encodeId=22cd193080637, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Fri Feb 26 17:21:07 CST 2021, time=2021-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795820, encodeId=23651e95820b5, content=<a href='/topic/show?id=9f491e726a3' target=_blank style='color:#2F92EE;'>#TRAF4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17726, encryptionId=9f491e726a3, topicName=TRAF4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Mon Aug 30 16:21:07 CST 2021, time=2021-08-30, status=1, ipAttribution=)]
    2021-02-26 smallant2002
  4. [GetPortalCommentsPageByObjectIdResponse(id=1657386, encodeId=07c6165e386b5, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Fri Jun 11 02:21:07 CST 2021, time=2021-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864288, encodeId=e152186428876, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Tue Feb 02 16:21:07 CST 2021, time=2021-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930806, encodeId=22cd193080637, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Fri Feb 26 17:21:07 CST 2021, time=2021-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795820, encodeId=23651e95820b5, content=<a href='/topic/show?id=9f491e726a3' target=_blank style='color:#2F92EE;'>#TRAF4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17726, encryptionId=9f491e726a3, topicName=TRAF4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Mon Aug 30 16:21:07 CST 2021, time=2021-08-30, status=1, ipAttribution=)]

相关资讯

Blood:CLL患者采用依鲁替尼作为一线疗法的成本效益

与三线应用相比,一线应用依鲁替尼(Ibrutinib)对大多数CLL患者不太可能具有成本效益; 一线药物依鲁替尼的月费用至少需要降低72%才能达到成本效益。

Blood:Bcl-2成员表达变化揭示了CLL维奈托克耐药机制

依鲁替尼和维奈托克治疗时,Bcl-2家族成员的表达会发生变化;依鲁替尼治疗后复发时,Bcl-2家族成员的表达又会恢复。在CLL维奈托克耐药发生过程中,相比Mcl-1,Bcl-XL发挥更重要的作用。

Blood:感染新冠病毒的CLL患者的预后

考虑到高龄、合并症和免疫功能障碍,CLL患者的感染风险可能特别高,与冠状病毒-19疾病(COVID-19)相关的预后较差。对CLL患者的预后进行可靠的分析,尤其是检查基线特征和CLL治疗的效果,对于在

Clin Cancer Res:随访8年!依鲁替尼治疗CLL/SLL长期有效!

一项Ib/II期PCYC-1102研究(NCT01105247) 证明了Bruton酪氨酸激酶(BTK)抑制剂依鲁替尼(1/日)在慢性淋巴细胞白血病/小淋巴细胞淋巴瘤(CLL/SLL)中的安全性和有效

Blood:CLL的高阶免疫球蛋白谱系限制:刻板化亚型#2 & #169

慢性淋巴细胞白血病(CLL)主要的刻板化亚型 #2 (IGHV3-21/IGLV3-21,约占所有CLL的2.5%) 是一个侵略性疾病变种, 且与克隆型IGHV基因的体细胞超突变(SHM)状态无关。次

Blood:慢性淋巴细胞白血病刻板化亚型之间的高阶联系

慢性淋巴细胞白血病(CLL)的特征是存在相同的、定型的B细胞受体免疫球蛋白(BcR IG)亚群。某些主要特定亚群的患者往往表现出非常一致的临床生物学特征,提示CLL的BcR IG刻板化的研究对了解疾病